

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **ISPH-0773**

Inventors: **Freier and Dobie**

Serial No.: **Not Yet Assigned**

Filing Date: **Herewith**

Examiner: **Not Yet Assigned**

Group Art Unit: **Not Yet Assigned**

Title: **Antisense Modulation of  
Phosphoinositide-3-Kinase, Regulatory  
Subunit4, P150 Expression**

"Express Mail" Label No. **EL977826891US**  
Date of Deposit **September 19, 2003**

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Commissioner for Patents, Mail Stop Sequence, P. O.  
Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata  
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents  
Mail Stop Sequence  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R.  
§§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).

**(XX)** In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

**( )** In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

**( )** Certification in Accordance with §1.97(e) is set forth below; or

**( )** The fee of **\$180.00** as set forth in §1.17(p) is attached.

**( )** In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of **\$130.00** as set forth in §1.17(I)(1).

**( )** Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

**(XX)** In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 10/160,786, filed May 31, 2002 for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

**(XX)** All listed references are in the English language.

Respectfully submitted,

*Jane Massey Licata*

Jane Massey Licata  
Registration No. 32,257

Date: September 19, 2003

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. ISPH-0773	Serial No. Not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Susan M. Freier et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date Herewith	Group
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Cantrell, <i>Phosphoinositide 3-kinase signalling pathways</i> , <i>J. Cell Sci.</i> , 2001, 114:1439-1445	
	AB	DeWald et al., <i>Regulation of the <i>Saccharomyces cerevisiae</i> Vps34p phosphatidylinositol 3-kinase</i> , <i>Biochem. Soc. Trans.</i> , 1997, 25:1141-1146	
	AC	Gillooly et al., <i>Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells</i> , <i>Embo J.</i> , 2000, 19:4577-4588	
	AD	Kihara et al., <i>Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in <i>Saccharomyces cerevisiae</i></i> , <i>J. Cell Biol.</i> , 2001, 152:519-530	
	AE	Nagle et al., <i>Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome</i> , <i>Nat. Genet.</i> , 1996, 14:307-311	
	AF	Panaretou et al., <i>Characterization of p150, an adaptor protein for the human phosphatidylinositol (PtdIns) 3-kinase. Substrate presentation by phosphatidylinositol transfer protein to the p150. Ptdins 3-kinase complex</i> , <i>J. Biol. Chem.</i> , 1997, 272:2477-2485	
	AG	Rochefort et al., <i>Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview</i> , <i>Clin. Chim. Acta</i> , 2000, 291:157-170	
	AH	Stein, <i>Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment</i> , <i>Endocr Relat Cancer</i> , 2001, 8:237-248	
	AI	Volinia et al., <i>A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system</i> , <i>Embo J.</i> , 1995, 14:3339-3348	
EXAMINER		DATE CONSIDERED	